SynAct Pharma Past Earnings Performance
Past criteria checks 0/6
SynAct Pharma's earnings have been declining at an average annual rate of -42.9%, while the Biotechs industry saw earnings growing at 7.7% annually.
Key information
-42.9%
Earnings growth rate
-31.2%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -91.4% |
| Net Margin | n/a |
| Next Earnings Update | 18 Feb 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How SynAct Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -155 | 29 | 46 |
| 30 Jun 24 | 0 | -166 | 34 | 48 |
| 31 Mar 24 | 0 | -191 | 37 | 69 |
| 31 Dec 23 | 0 | -216 | 34 | 105 |
| 30 Sep 23 | 0 | -156 | 48 | 116 |
| 30 Jun 23 | 0 | -148 | 44 | 115 |
| 31 Mar 23 | 0 | -129 | 42 | 100 |
| 31 Dec 22 | 0 | -99 | 36 | 70 |
| 30 Sep 22 | 0 | -95 | 33 | 69 |
| 30 Jun 22 | 0 | -89 | 31 | 64 |
| 31 Mar 22 | 0 | -78 | 22 | 63 |
| 31 Dec 21 | 0 | -69 | 16 | 60 |
| 30 Sep 21 | 0 | -52 | 15 | 46 |
| 30 Jun 21 | 0 | -41 | 12 | 37 |
| 31 Mar 21 | 0 | -35 | 10 | 29 |
| 31 Dec 20 | 0 | -27 | 9 | 23 |
| 30 Sep 20 | 0 | -29 | -1 | 32 |
| 30 Jun 20 | 0 | -24 | 1 | 25 |
| 31 Mar 20 | 0 | -23 | 6 | 20 |
| 31 Dec 19 | 0 | -24 | 10 | 15 |
| 30 Sep 19 | 0 | -20 | 23 | 0 |
| 30 Jun 19 | 0 | -23 | 26 | 0 |
| 31 Mar 19 | 0 | -24 | 30 | 0 |
| 31 Dec 18 | 0 | -23 | 6 | 22 |
| 30 Sep 18 | 0 | -23 | 28 | 0 |
| 30 Jun 18 | 0 | -19 | 23 | 0 |
| 31 Mar 18 | 0 | -15 | 18 | 0 |
| 31 Dec 17 | 0 | -15 | 18 | 0 |
| 30 Sep 17 | 0 | -23 | 25 | 0 |
| 31 Dec 16 | 0 | -21 | 22 | 0 |
| 31 Dec 15 | 0 | -1 | 0 | 0 |
Quality Earnings: 8F8 is currently unprofitable.
Growing Profit Margin: 8F8 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 8F8 is unprofitable, and losses have increased over the past 5 years at a rate of 42.9% per year.
Accelerating Growth: Unable to compare 8F8's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 8F8 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 8F8 has a negative Return on Equity (-91.37%), as it is currently unprofitable.